top of page

Nutrition in 2024: GLP-1 Medications, Personalized Eating and What Comes Next

  • Writer: Nicole Barrato
    Nicole Barrato
  • Jan 15, 2024
  • 2 min read

Updated: 4 hours ago

We begin 2024 at a genuinely pivotal moment in nutrition and metabolic medicine. The GLP-1 medication revolution — semaglutide and tirzepatide have now collectively reached tens of millions of patients — is reshaping how clinicians, patients and the nutrition profession think about weight, metabolism and the role of dietary intervention. At the same time, the personalized nutrition field is maturing rapidly, with continuous glucose monitors, microbiome testing and advanced biomarker panels becoming more accessible tools for individuals seeking to understand their own metabolic responses to food.

For those on GLP-1 medications, 2024 will be a year of increasing evidence about optimal nutritional management during and after treatment. The primary concern is lean mass preservation: patients losing weight rapidly on these medications who do not prioritize protein intake and resistance exercise risk losing meaningful amounts of muscle, which has significant metabolic consequences. Prioritizing 25 to 40 grams of protein per meal, maintaining as much dietary variety as appetite allows and engaging in resistance training are the core strategies emerging from the clinical literature.

The broader nutrition landscape in 2024 continues to favor food quality over macronutrient arithmetic. The evidence for ultra-processed food reduction, diverse plant intake and the Mediterranean dietary pattern as a foundation continues to strengthen. What is new and exciting is the growing ability to personalize these evidence-based principles to individual biology. Working with a registered dietitian at NutriGreene gives you access to the tools and expertise to make that personalization a reality in your own life this year.

Sources

  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

  • Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.

Ready to take the next step in your nutrition journey? Schedule an appointment at NutriGreene today. www.nutrigreene.com | (203) 429-4211 | info@nutrigreene.com

Comments


bottom of page